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We have previously shown that an Escherichia coli-expressed, denatured spike (S) protein fragment of the
severe acute respiratory coronavirus, containing residues 1029 to 1192 which include the heptad repeat 2
(HR2) domain, was able to induce neutralizing polyclonal antibodies (C. T. Keng, A. Zhang, S. Shen, K. M. Lip,
B. C. Fielding, T. H. Tan, C. F. Chou, C. B. Loh, S. Wang, J. Fu, X. Yang, S. G. Lim, W. Hong, and Y. J. Tan,
J. Virol. 79:3289–3296, 2005). In this study, monoclonal antibodies (MAbs) were raised against this fragment
to identify the linear neutralizing epitopes in the functional domain and to investigate the mechanisms involved
in neutralization. Eighteen hybridomas secreting the S protein-specific MAbs were obtained. Binding sites of
these MAbs were mapped to four linear epitopes. Two of them were located within the HR2 region and two
immediately upstream of the HR2 domain. MAbs targeting these epitopes showed in vitro neutralizing
activities and were able to inhibit cell-cell membrane fusion. These results provide evidence of novel neutral-
izing epitopes that are located in the HR2 domain and the spacer region immediately upstream of the HR2 of
the S protein.
The virus-cell membrane fusion event is an essential step in
the entry process of all enveloped animal viruses, including
important human pathogens such as influenza virus, human
immunodeficiency virus (HIV) (8, 23), and the newly emerged
severe acute respiratory syndrome coronavirus (SARS-CoV)
(9). Following the binding to their receptors on the cell surface,
virus-encoded membrane fusion proteins mediate the fusion
process. In many but not all cases, the viral fusion proteins are
proteolytically processed by host proteases into 2 subunits that
remain closely associated with each other: a surface subunit
with a receptor-binding site and a transmembrane subunit with
a fusion peptide consisting of two or more heptad repeat do-
mains. Upon interaction of the fusion protein with a cellular
receptor, the buried fusion peptide is exposed and inserted into
the membrane of the target cell. A series of conformational
changes trigger virus-cell fusion activity (9) and lead to the
unloading of the viral genome into cells. Additionally, many
viral fusion proteins also induce cell-cell fusion, i.e., the for-
mation of multinucleated syncytia, facilitating the rapid spread
of virus infection.
The spike (S) protein of coronaviruses is responsible for
receptor binding and membrane fusion. It shares similarity
with class I virus fusion proteins (2, 3). Typically, it is a type I
integral membrane protein, which is N-glycosylated and trim-
erized in the endoplasmic reticulum. The N-terminal S1 pro-
tein contains the receptor-binding site (10, 18, 22, 34). The
C-terminal S2 protein is a fusion subunit and anchors on the
viral envelope through a transmembrane domain. The S2 pro-
tein ectodomain contains two 4,3 hydrophobic heptad repeats
(HR1 and HR2) and a putative, internal fusion peptide (3, 23).
For the SARS-CoV S protein, the HR2 is located adjacent to
the transmembrane domain, whereas the HR1 is 140 to 170
residues upstream of the HR2.
Crystallographic, biophysical, and biochemical analysis of
the fusion core of SARS-CoV S protein (2, 12, 19, 27, 30, 35)
and other class I fusion proteins (8, 25) supports a model of
membrane fusion probably adopted by these enveloped vi-
ruses. After the attachment of the receptor-binding subunit to
the receptor, the HR1 and HR2 domains in the membrane
fusion subunit interact with each other and form a six-helix
bundle, a complex consisting of a homotrimeric HR1 coiled
coil surrounded by three HR2 helices. The spacer domain (or
link, or interhelical domain) between HR1 and HR2 forms a
loop and reverses the direction of the polypeptide chain so that
the HR2 helices pack against the HR1 coiled coil in an anti-
parallel manner. This conformational change results in a close
apposition of the fusion peptide, already exposed and inserted
into the target cellular membrane, with the viral transmem-
brane domain, leading to virus-cell membrane fusion. Obvi-
ously, the functional domains involved in membrane fusion are
attractive targets for the discovery of viral entry inhibitors.
Peptides derived from HR1 or HR2 can inhibit infection as
shown for coronaviruses and many other viruses, presumably by
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interfering with the formation of the six-helix bundle and inhib-
iting the initiation of membrane fusion. This strategy has been
successfully used in the development of inhibitors for HIV infec-
tion (20). Potentially, monoclonal antibodies (MAbs) targeting
fusion subunits might also inhibit the fusion in the same manner
(21). For example, neutralizing MAbs against gp41 of HIV are
likely to target fusion intermediates or epitopes that are exposed
following receptor interactions (39, 41).
The S protein contains the determinants for host specificity,
cell tropism, and pathogenesis. The S protein is also able to
stimulate humoral and cellular immune responses (1, 6, 7, 13,
32), and therefore, it is one of the major targets for the devel-
opment of vaccine candidates. Identification and characteriza-
tion of neutralizing epitopes on S of SARS-CoV could provide
useful leads to the development of efficacious vaccines (11, 26,
31, 37, 38). In our previous study (15), we have shown that an
Escherichia coli-expressed fragment induces neutralizing poly-
clonal antibodies targeting domains involved in membrane fu-
sion. In this study, monoclonal antibodies were generated using
the same S fragment to determine the neutralizing antigenic sites
in this region. The activities of in vitro neutralization and
inhibition of cell-cell membrane fusion of the MAbs were
tested in order to determine the mechanism involved in the
neutralization of virus infectivity. The results showed that bind-
ing of MAbs to the functional domains might interfere with the
interaction between the HR1 and HR2 domains required for
membrane fusion and virus entry.
MATERIALS AND METHODS
Cells and viruses. Cos-7, CHO, Vero E6, and 293T cells were purchased from
the American Type Culture Collection (Manassas, Va.) and were maintained in
Dulbecco’s modified Eagle medium (DMEM; Sigma-Aldrich Inc.) supplemented
with 10% fetal calf serum (HyClone), streptomycin (1,000 g/ml), and penicillin
(1,000 U/ml). A CHO cell line (CHO-ACE2) stably expressing the receptor,
ACE2, for SARS-CoV S was established using the methods described previously
and grown in complete DMEM containing 0.1 mM ZnSO4 (4). The strain
Sin2774 of SARS-CoV (GenBank accession number AY283798) was isolated
from a SARS patient in Singapore General Hospital and was adapted to grow in
Vero E6 cells. Recombinant vaccinia/T7 virus (vTF7-3) was grown and titrated
on Vero E6 cells. Recombinant vaccinia viruses rVV-L-SP and rVV-L-NP ex-
pressing the S and N proteins of SARS-CoV, respectively, were obtained from
Baxter Vaccines and grown in CV-1 cells.
Construction of plasmids for expression in mammalian cells. A plasmid
pKT-S containing the S gene of SARS-CoV was prepared as described previously
(15). Specific primers were designed for two-round PCR to amplify S fragments
with internal deletions of the S gene from nucleotide positions 3084 to 3150, 3151
to 3210, 3211 to 3270, 3271 to 3330, 3331 to 3390, 3391 to 3450, 3451 to 3510, and
3511 to 3576, respectively (numbering according to the S gene of strain Sin2774).
The eight PCR products were digested with EcoRV and SacI and ligated to
EcoRV/SacI-cut pKT-S under the control of a T7 promoter, giving rise to
plasmids pKT-S50, pKT-S51, pKT-S52, pKT-S53, pKT-S54, pKT-S55,
pKT-S56, and pKT-S57, respectively.
Generation of monoclonal antibodies. Glutathione S-transferase (GST)- and
His-tagged fusion proteins GST-S10 and S10-His were expressed in E. coli
and purified as described previously (15). They were used for immunization of
mice and screening of hybridomas secreting S-specific MAbs, respectively. Each
of the 6-week-old female BALB/c mice was given primary injection (intraperi-
toneal) with 100 g of the protein GST-S10 emulsified in complete Freund’s
adjuvant (Sigma-Aldrich Inc.). Two weeks later, each mouse was given one
secondary booster injection using the same amount of antigen mixed with in-
complete Freund’s adjuvant (Sigma-Aldrich Inc.). Booster injections were ad-
ministered to each mouse at 1-week intervals three more times. S-specific anti-
bodies in the serum of immunized mice were tested by Western blot assays prior
to hybridoma fusion. The spleen was excised, and hybridoma fusion was per-
formed using the ClonalCell-HY Complete kit (StemCell Technologies, Canada)
according to the manufacturer’s instructions. All procedures on the use of lab-
oratory animals were done in accordance with the regulations and guidelines of
the National Advisory Committee for Laboratory Animal Research, Singapore.
MAbs in supernatants of hybridoma cultures were screened in an enzyme-linked
immunosorbent assay (ELISA). Briefly, 96-well ELISA plates were coated with
the protein S10-His or bovine serum albumin (50 ng/well) in 0.1 M sodium
carbonate buffer (pH 9.6) overnight at 4°C. The plates were blocked with phos-
phate-buffered saline (PBS) containing 5% fetal calf serum and 0.05% Tween 20
for 1 h at 37°C and washed three times with PBS containing 0.05% Tween 20 and
three times with PBS. Supernatants of hybridoma cultures (50 l/well) were
incubated for 1 h at 37°C. After washing, goat anti-mouse immunoglobulin G
(IgG)-horseradish peroxidase antibodies (200 g/ml, Santa Cruz, Calif.) at a
dilution of 1:2,500 were added to the ELISA plates, which were then incubated
for 1 h at 37°C. After washing three times with PBS, substrate TMB (Pierce
Biotechnology) was added and the reaction was stopped 15 min later by adding
an equal volume of 1 M H2SO4. Optical density was read at 450 nm. Mouse
immune and preimmune sera were used as positive and negative controls. Sam-
ples giving a value of optical density that is equal or greater than 3 standard
deviations above the mean value of bovine serum albumin controls were con-
sidered positive.
Western blot analysis of the S protein in transfected Cos-7 cells and infected
Vero E6 cells. To prepare lysates of S-transfected cells, 50% of confluent mono-
layers of Cos-7 cells in 60-mm petri dishes was infected at a multiplicity of
infection (MOI) of 1 with recombinant vaccinia virus vTF7-3 expressing bacte-
riophage T7 RNA polymerase. After 1 h of adsorption, cells were transfected
with 2 to 4 g of plasmid by using Effectene reagents (QIAGEN) according to
the manufacturer’s instruction. Transfected cells were incubated overnight at
37°C, and the cell lysate was prepared by resuspending the cell pellet in 1
protein sample buffer (60 mM Tris-HCl [pH 6.8], 1% sodium dodecyl sulfate
[SDS], 20 mM dithiothreitol, 10% glycerol, 0.02% bromophenol blue). To pre-
pare lysates of SARS-CoV-infected cells, confluent Vero E6 cells were infected
with viruses at an MOI of 1 and were incubated at 37°C for 12 to 15 h. Cells were
washed with PBS and were resuspended in lysis buffer containing 150 mM NaCl,
20 mM Tris (pH 7.5), 1% NP-40, 5 mM EDTA, and 1 mM phenylmethylsulfonyl
fluoride. One volume of 5 standard protein sample buffer was added to 4
volumes of cell lysate. The samples were heated at 100°C for 5 min and were kept
at 20°C before use. Proteins in cell lysates were separated by 10% polyacryl-
amide gel electrophoresis and transferred to a nitrocellulose membrane. The
membranes were blocked in 5% nonfat milk in PBS with 0.05% Tween 20 and
probed with either rabbit anti-S10 serum (1:20,000) or MAbs (1:4,000) at 4°C
overnight. The membranes were incubated with goat anti-rabbit or anti-mouse
horseradish peroxidase-conjugated secondary antibodies (200 g/ml; Santa
Cruz) at a dilution of 1:2,000 for 1 h at room temperature and developed with
enhanced chemiluminescence reagent (Pierce).
In vitro virus neutralization assay. Neutralization assays were performed in a
96-well plate format. Complement proteins in ascitic fluids were inactivated at
56°C for 30 min before use. MAbs were first diluted 10 times, and then serial
twofold dilutions were prepared in maintenance medium. One set of antibody
dilutions was added to cells to detect the toxicity of the ascitic fluids. The diluted
antibodies were incubated with 10 50% tissue culture infective doses of SARS-CoV
in an equal volume of medium for 1 h at 37°C before being added into the
respective wells containing 5  104 Vero E6 cells per well. At each dilution, the
mixtures of antibody and virus were added to four wells and incubated with Vero
E6 cells. After 3 days, cytopathic effect (CPE) developed in all the negative
controls and the back titration wells. The titers of the neutralizing antibodies
were determined by applying the Ka¨rber formula: Negative log of the lowest
dilution  [(sum of percentage positive/100)  0.5]  log interval. All experi-
ments were carried out in triplicate, and the neutralizing titers were expressed as
the reciprocal of the highest antibody dilution where the viral CPE in 50% of the
wells was neutralized.
Fluorescence activated cell sorting (FACS) analysis. 293T cells infected with
rVV-L-SP expressing the S proteins (293T-SP) and stable cell line CHO-ACE2
were first detached with 0.04% EDTA, washed once with PBS, and incubated
with rabbit anti-S10 serum diluted 1:40, MAbs or goat anti-ACE2 IgG primary
antibodies (100 g/ml; Santa Cruz) diluted 1:20 in PBS containing 1% fetal
bovine serum and 0.1% sodium azide for 1 h at 4°C. Cells in tubes were placed
on a roller to ensure constant mixing under nonpermeabilizing conditions. The
cells were washed and subsequently incubated with fluorescein isothiocyanate
(FITC)-labeled goat anti-rabbit IgG (200 g/ml; Santa Cruz), rabbit anti-goat
IgG secondary antibodies (200 g/ml; Santa Cruz), or goat anti-mouse IgG
secondary antibodies (200 g/ml; Santa Cruz) at a 1:20 dilution for 1 h at 4°C and
placed on a roller to ensure constant mixing. Immediately after washing, cells
were measured for FITC fluorescence using a Becton Dickinson FACScan flow
cytometer and results were analyzed using Cellquest Pro software.
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Cell-cell membrane fusion assay. The 293T effector cells were transfected with
plasmid pEGFP-N1 (Clontech Laboratories Inc, Pala Alto, Calif.), which en-
codes GFP, using Effectene transfection reagent (QIAGEN) according to the
manufacturer’s instructions. After 24 h, medium was removed and the cells were
washed twice with room temperature PBS before the infection medium was
added. Effector cells were infected with recombinant vaccinia virus expressing
the SARS-CoV spike protein (rVV-L-SP) at an MOI of 0.1. After 1 h of
adsorption, the infection medium was removed and subsequently replaced with
complete DMEM for 24 h for S expression. The effector cells and target cells
(CHO-ACE2) were first detached with 0.04% EDTA, washed once with PBS,
and resuspended in DMEM containing 0.25 mg/ml porcine trypsin (JRH Bio-
sciences Inc.) and 5.6% fetal bovine serum. Target and effector cells were mixed
at a 1:1 ratio per well (up to 1  106 cells) in a 12-well plate (Nunc). Syncytium
formation was observed 6 h after mixing of cells.
Inhibition of syncytium formation. Effector and target cells were prepared as
described above. Serially diluted rabbit anti-S10 serum (at a dilution factor of
1:40, 1:80, 1:160), preimmune serum (at a dilution factor of 1:40), or serially
diluted MAbs (at dilution factor of 1:40, 1:80, 1:160) were preincubated with
effector cells at 37°C for 10 min. To maintain the same antibody concentration
used in the preincubation, more antibodies were added together with the target
cells to the fusion medium to complete the cell-cell membrane fusion assay.
Inhibition of syncytium formation could be observed from 6 h onwards. Five
micrographs were taken randomly in a 10 magnified field of view on an
Olympus UV microscope CKX41 equipped with an Olympus Camedia C-5060
digital camera. Syncytium with a size equal to or greater than 10 cells was
considered a true fusion, and the average numbers of syncytia were scored. The
total number (T) of possible syncytia without cell-cell membrane fusion inhibi-
tion was derived from fusion experiment with non-SARS-CoV-related mouse
ascitic fluid (anti-dengue MAb serotype I 6F8-3) or rabbit preimmune serum.
The number (I) of syncytia with inhibition effect was derived from fusion exper-
iments in the presence of specific antibodies of interest. Percent inhibition of
cell-cell membrane fusion was expressed as (TI)/T.
RESULTS
Generation of monoclonal antibodies against S10 region.
Our previous work showed that an S region covering the entire
HR2 domain and its upstream region induced neutralizing
polyclonal antibodies in immunized animals, which might bind
to linear epitopes (15). To identify linear neutralizing epitopes
and characterize functional domains in this region, monoclonal
antibodies were generated against the region covering residues
1029 to 1192 of the S protein. By using bacterially synthesized
S fragment GST-S10 (15) as an antigen, BALB/c mice were
immunized and then boosted up to four times. Sera were
collected 1 week after booster injections were given and tested
for the presence of specific antibodies by Western blot assays.
An antibody response was observed after the first booster
injection was given (at a serum dilution of 1:1,000) (data not
shown), indicating that the GST-S10 fragment was highly
immunogenic in terms of inducing antibodies in mice. After
hybridoma fusion and hypoxyanthine-aminopterin-thymidine
selection, culture supernatants of individual clones were screened
by ELISA using a C-terminally His-tagged S fragment (S10-
His) covering the same region of S. This helped to eliminate
clones that were reacting to GST antigenic determinants.
Among 125 ELISA-positive hybridomas, 94 (75%) were posi-
tive in Western blot screening using the full-length S protein
prepared in a vaccinia-T7 expression system in Cos-7 cells (15).
These hybridomas were passaged twice, and the supernatants
were retested in Western blot assays. The results indicated that
48 out of 94 (51%) hybridomas were stably secreting specific
monoclonal antibodies. Among them, 18 hybridomas (37.5%)
produced a higher concentration of MAbs in supernatants,
which were used for the mapping of binding sites. Eight out of
the 18 hybridomas (44%) were subcloned and used to generate
ascitic fluids, which were characterized in neutralizing and
membrane fusion blocking assays as described below.
Detection of the S protein in SARS-CoV-infected cells by
monoclonal antibodies. To confirm the binding specificity of
MAbs to the S protein, all monoclonal antibodies were used to
detect the S protein in virus-infected Vero E6 cells. Represen-
tative gels are shown in Fig. 1A. The MAbs could detect the
210-kDa S protein in infected (lanes 2, 4, 6, and 8) but not in
mock-infected (lanes 1, 3, 5, and 7) cells. The results demon-
strated that the monoclonal antibodies were specifically bind-
ing to the S protein in SARS-CoV-infected cells. The MAbs
against the S10 region recognize the full-length S protein
synthesized in virus-infected Vero E6 cells, consistent with
previous results (15) obtained using rabbit anti-S10 poly-
clonal antibodies.
Mapping of binding sites of monoclonal antibodies. To de-
termine the binding sites of the MAbs, eight internal deletion
mutant plasmids were constructed, expressed in Cos-7 cells,
and used to determine the linear binding sites of MAbs by
Western blot analysis. Each of these mutants encodes an S
protein with a 20- or 22-residue deletion (20 to 22 residues
shorter than the full-length S protein). The positions of the
FIG. 1. (A) Detection of the S protein in virus-infected Vero E6
cells. Vero E6 cells were infected with SARS-CoV at an MOI of 1
(lanes 2, 4, 6, and 8) or mock infected (lanes 1, 3, 5, and 7) for 24 h.
Cell lysates were separated on SDS–10% polyacrylamide gels and
analyzed in Western blots using MAbs 2B2, 1A9, 4B12, and IG10.
Molecular weight markers are indicated to the left. Position of the S
protein is indicated by an arrowhead to the right. (B) Mapping of
binding sites of monoclonal antibodies. The S mutant proteins (lanes 1
to 8, S50 to S57) with an internal 20- or 22-residue deletion were
synthesized in a vaccinia-T7 expression system in Cos-7 cells. Cell
lysates were separated on SDS–10% polyacrylamide gels and analyzed
in Western blots using type I, II, III, and IV monoclonal antibodies and
polyclonal antibody rabbit -S10 as indicated to the right of the gels.
Mock-transfected cell lysate (lane 9) was used as a negative control
(Cont.). Molecular weight markers are indicated to the left.
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deleted amino acid residues are indicated in Table 1. The
binding sites of MAbs from 18 hybridomas were mapped, and
the results were shown by representative gels in Fig. 1B. In
transfected cells, the unglycosylated form of S was produced
(15). Both glycosylated and unglycosylated forms (bottom gel,
lanes 1 to 8) of each mutant protein (S50 to S57) were
detected using rabbit anti-S10 serum. These were S-specific
proteins, as no bands were detected in mock-transfected cells
(lane 9). In contrast, S proteins encoded by one or two mutant
constructs were not detected by each of the four types of
MAbs; therefore, these MAbs bound to residues that were
deleted in the corresponding internal-deletion mutants. As
summarized in Table 2, 18 MAbs bound to four distinct anti-
genic sites and therefore were classified into types I (6 of 18),
II (4 of 18), III (5 of 18), and IV (3 of 18). The type I, II, III,
and IV MAbs bound to residues 1091 to 1130, 1111 to 1130,
1151 to 1170, and 1151 to 1192, respectively. The results
showed that residues 1091 to 1192 of the S10 fragment har-
bor the major antigenic epitopes, but not the residues 1029 to
1090. Antigenic site I (1091 to 1130) overlapped with site II
(1111 to 1130), while antigenic site III (1151 to 1170) over-
lapped with site IV (1151 to 1192). Despite the overlap, each
site was distinct from the other. It seems that these antigenic
sites were immunodominant within the S10 region (residues
1029 to 1192).
In vitro neutralization of virus infectivity by MAbs. Ascitic
fluids of eight MAbs, all of which are of the immunoglobulin
isotype 1, were prepared, and antibody concentrations of crude
preparations were determined (Table 3). The ascitic fluids
were diluted 10 times, and then serial twofold dilutions were
prepared. Neutralization assays were performed in a 96-well
plate format by incubating equal volumes of diluted antibodies
and virus suspension containing 10 50% tissue culture infective
doses for 1 h at 37°C and then adding the mixtures to confluent
Vero E6 cells in wells. After 3 days, complete CPE was ob-
served in all control wells containing virus suspension in the
absence of antibodies of interest and in wells containing anti-
dengue MAb (non-SARS-CoV related) or a nonneutralizing
MAb, 7G12-6, targeting amino acid residues 281 to 300 of S.
Ascitic fluids were not cytotoxic at the starting concentration
used. The neutralizing titers were expressed as the reciprocal
of the final dilution of antibodies required to completely pro-
tect cells in 50% of the wells (no CPE was observed) from virus
infection. As shown in Table 3, all four types of MAbs showed
neutralizing activities with titers ranging from 24 to 75 at MAb
concentrations ranging from 13 to 100 g/ml. The results
showed that the amino acid residues, which the MAbs bound
to, might represent the neutralizing epitopes on the S protein.
Neutralizing MAbs binding to regions upstream of and
within the HR2 domain. The amino acid sequence of the re-
gion (residues 1091 to 1192), which the four types of mono-
clonal antibodies target, were aligned with those of the corre-
sponding S regions of other coronaviruses (Fig. 2). The HR2
domain of the SARS-CoV S protein has been predicted to be
located within residues 1125 to 1193 or 1144 to 1191 (3, 35).
Therefore, the upstream region from residues 1091 to 1124 or
1143 is considered a part of the spacer region between HR1
and HR2. As shown in Fig. 2, type I and II MAbs bound to the
spacer region immediately upstream of HR2, residues 1091 to
1131 and 1111 to 1131, respectively. Type III and IV MAbs
bound directly to the HR2 domain (residues 1151 to 1192). As
indicated in Fig. 2, these neutralizing epitopes on SARS-CoV
S protein were different from the amino acid residues SIAPD
LSLDFEKLNV (shown by a line with arrows at the both ends)
bound by the neutralizing MAb of the murine hepatitis virus
(MHV) S protein characterized previously (21). The results
suggested that the HR2 domain and the spacer region imme-
diately upstream of HR2 harbored neutralizing epitopes and
therefore might be functionally important domains.
Inhibition of S-induced cell-cell membrane fusion by MAbs.
During the virus entry into cells, the HR1 and HR2 domains
interact with each other and a subsequent conformational
change triggers virus-cell membrane fusion. To test if the an-
tibodies targeting this functional region could interfere with
the HR1 and HR2 interaction and block membrane fusion, a
cell-cell membrane fusion assay was developed. Effector cells,
293T, infected with rVV-L-SP, expressing S proteins (293T-SP),
and the target cells, CHO-ACE2, expressing receptor ACE2,
were used to achieve this end.
TABLE 1. Reactivity of MAbs against the internal-deletion
S mutants
Mutant
protein Residues deleted
MAb typea
I II III IV
S50 1029–1050    
S51 1051–1070    
S52 1071–1090    
S53 1091–1110    
S54 1111–1130    
S55 1131–1150    
S56 1151–1170    
S57 1171–1192    
a , MAb binds to protein; , MAb does not bind protein.
TABLE 2. Binding sites
Binding site Mab type % of hybridomas(no./total no.)
1091–1130 I 33.3 (6/18)
1111–1130 II 22.2 (4/18)
1151–1170 III 27.7 (5/18)
1151–1192 IV 16.6 (3/18)
TABLE 3. In vitro neutralizing activities of MAbs
MAb MAbtype Isotype Titers
IgG
(g/ml)
2B2 I IgG1 40 50
2G2 I IgG1 47 85
1A9 II IgG1 28 35
1C6 III IgG1 24 83
1H1 III IgG1 40 100
6B9 III IgG1 24 42
4B12 III IgG1 47 42
1G10 IV IgG1 75 13
7G12 IgG1 0 50
Anti-dengue IgG1 0 50
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First, FACS analysis was performed to verify that the S and
ACE2 proteins were expressed on the cell surface of 293T-SP
and CHO-ACE2 cells, respectively, under nonpermeabilizing
conditions. 293T-SP cells were incubated with rabbit anti-S10
primary antibodies, and CHO-ACE2 cells were incubated with
goat anti-ACE2 primary antibodies. The cells were subse-
quently incubated with FITC-conjugated goat anti-rabbit or
rabbit anti-goat IgG secondary antibodies. As shown in Fig. 3A
(left), FITC fluorescence intensity measured for CHO-ACE2
was higher than that for control cells CHO, indicating expres-
sion of ACE2 proteins on the surface of CHO-ACE2 cells. As
shown in Fig. 3A (right), FITC fluorescence measured for
293T-SP was higher than that for control cells 293T-NP ex-
pressing the N (nucleocapsid) protein of SARS-CoV. In an-
other parallel FACS experiment, rabbit anti-S10 or preim-
mune serum was incubated with 293T-SP and FITC
fluorescence intensity measured for rabbit anti-S10 was sig-
nificantly higher than that for control preimmune serum (data
not shown). These results indicated that S was presented on
the cell surface.
To investigate if the epitopes upstream of HR2 (types I and
II) and within HR2 (types III and IV) are exposed and acces-
sible to specific antibodies, eight MAbs of interest (1:20) or an
unrelated anti-dengue MAb was incubated with the effector
cells, 293T-SP. The cells were subsequently incubated with
FITC-conjugated goat anti-mouse IgG secondary antibodies.
The interaction between the MAbs and S was measured by
FACS analysis. In Fig. 3B, a representative histogram of each
type of MAb (type I MAb, 2B2; type II MAb, 1A9; type III
MAb, 4B12; type IV MAb, 1G10) is shown. Generally, FITC
fluorescence intensity measured for each MAb was signifi-
cantly higher than that for control anti-dengue MAb. This
indicated that the eight MAbs could bind to the four epitopes
on S and that these epitopes on the S proteins were exposed
and accessible to specific antibodies.
Next, a cell-cell membrane fusion assay was set up for syn-
cytium formation. Effector cells, 293T-SP or 293T-NP, trans-
fected with pEGFP-N1 (expressing green fluorescent protein
[GFP]) were incubated with either target CHO-ACE2 or nor-
mal CHO cells. All cell-cell membrane fusion experiments
were done in triplicate. A representation of the morphology of
normal cells and cells that have undergone cell-cell fusion is
shown in Fig. 3C. As seen in the top row, syncytium formation
with 10 or more cells fused together as a result of the interac-
tion between S and ACE2, which were expressed on the sur-
faces of effector cells, 293T-SP, and target cells, CHO-ACE2,
was displayed in a bright field (left), a dark field under UV
excitation (right), and a combined view (center). In contrast,
no syncytium was observed when control effector cells, 293T-NP,
were incubated with CHO-ACE2 (Fig. 3C, bottom micro-
graphs). In Fig. 3C (bottom micrographs), individual cells were
well distinguishable with a clear cell boundary in the bright
field (left) and as single spots of green fluorescence in the dark
field (right), in contrast to the lack of cell boundaries and
massive bodies of green fluorescence as shown in Fig. 3C, top
micrographs. 293T-SP incubated with normal CHO cells did
not yield any syncytia in the fusion experiments (data not
shown). Only fusion experiments consisting of effector cells,
293T-SP, and target cells, CHO-ACE2, could form syncytia.
These results confirmed that the cell-cell membrane fusion
assay was induced by S and was dependent on the receptor
ACE2 (18, 24, 26).
In order to investigate the inhibition of syncytium formation
by specific antibodies, the four types of MAbs comprised of 8
MAbs (2B2 and 2G2 in type I; 1A9 in type II; 1C6, 1H1, 4B12,
and 6B9 in type III; and 1G10 in type IV), a non-SARS-CoV-
FIG. 2. Clustal W multiple sequence alignment of coronavirus S proteins. The S region corresponding to the binding sites of monoclonal
antibodies to SARS-CoV (Singapore strain 2774) is aligned with those of the group 1 coronaviruses feline infectious peritonitis virus (FIPV) and
human coronavirus 229E (HCoV-229E), the group 2 coronaviruses HCoV-OC43 and MHV-59A (mouse hepatitis virus), and the group 3
coronavirus infectious bronchitis virus (IBV) (GenBank accession numbers AY283798, VGIH79, VGIHHC, CAA83661, VGIH59, and M95169,
respectively). The shading indicates sequence identity and similarity. The predicted HR2 region and upstream spacer region and binding sequences
of type I, II, III, and IV monoclonal antibodies are shown by arrows and lines. The line with arrows at both ends represents the binding site of
a neutralizing MAb against S of MHV (23).
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FIG. 3. (A) FACS analysis of the surface expression of the S and ACE2 proteins. Left, ACE2 surface expression on CHO-ACE2 stable cells
(solid line) and negative control CHO cells (dotted line) was probed with goat anti-ACE2 primary and FITC-conjugated anti-goat IgG secondary
antibodies. Right, S protein surface expression (solid line) and nucleocapsid protein expression (dotted line; negative control) on 293T cells was
probed with rabbit anti-S10 primary and FITC-conjugated anti-rabbit IgG secondary antibodies. (B) FACS analysis of the four epitopes located
upstream of HR2 and within HR2 on S. Effector cells, 293T-SP, were probed with four representative MAbs of interest and an unrelated
anti-dengue MAb, followed by FITC-conjugated anti-mouse IgG secondary antibodies. Top left panel, S was probed with type I MAb 2B2 (solid
line) and anti-dengue MAb (dotted line). Top right panel, S was probed with type II MAb 1A9 (solid line) and anti-dengue MAb (dotted line).
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related anti-dengue MAb, rabbit anti-S10 serum, or rabbit
preimmune serum and goat anti-ACE2 antibody were incu-
bated in the cell-cell membrane fusion assay at 1:40, 1:80, and
1:160 dilutions, respectively. Rabbit anti-S10 serum and goat
anti-ACE2 antibody were included as positive controls, and
rabbit preimmune serum and anti-dengue MAb were included
as negative controls. Representative micrographs of syncytium
formation between effector and target cells are shown in Fig. 4A.
Syncytium formation was not observed in the presence of 1:40
diluted rabbit anti-S10 serum (top right) or MAb 1A9 (bot-
tom right). No syncytium formation was observed in the pres-
ence of goat anti-ACE2 antibody (data not shown). In contrast,
as shown in the left panels, large syncytia were observed in the
presence of 1:40 noninhibiting rabbit preimmune serum (top
left) or anti-dengue MAb (bottom left).
Next, the distribution of the number of nuclei per syncytium
was scored. It was found that syncytia formed from 10 or more
cells accounted for at least 90% of all potential syncytia scored
(data not shown). Only syncytia with 10 nuclei or more were
counted in order to eliminate artifacts scored as a result of cell
division or abnormal cell clumping and to avoid difficulty in
determining syncytia of small size. This formed the basis for
scoring true fusion for subsequent cell-cell fusion assays.
The number of syncytia was then scored, and the percent-
age of the syncytium inhibition at different antibody dilu-
tions is summarized in Fig. 4B. At a 1:40 dilution, all the
MAbs inhibited more than 50% of syncytium formation.
However, syncytia inhibition decreased significantly when
each MAb was serially diluted from 1:40 to 1:80 and 1:160.
The formation of syncytia was inhibited in a dose-dependent
manner, indicating that the MAbs were specific in blocking
cell-cell membrane fusion.
DISCUSSION
An attractive approach to interfere with viral infection and
prevent SARS is to block the virus-cell membrane fusion using
inhibitory drugs (peptides or nonpeptides) or neutralizing an-
tibodies binding to domains involved in membrane fusion. Pep-
tides derived from the HR1 or HR2 domains of viral fusion
glycoproteins can effectively inhibit virus infections caused by
retroviruses, paramyxoviruses, and coronaviruses (3, 14, 17,
33). It has been demonstrated that peptides derived from the
HR2 domain of S could inhibit the in vitro replication of
SARS-CoV, although less effectively than the similar peptides
against the S protein of MHV (3). Binding sites of several
neutralizing MAbs were mapped to linear epitopes on S2 of
MHV 59A and predicted to form a coiled coil and to be involved
in membrane fusion (8). In this study, an S fragment was used
to immunize mice, as it could induce neutralizing polyclonal
antibodies (15). MAbs were generated and analyzed by West-
ern blot using S deletion mutants. Binding sites of the MAbs
were mapped to linear epitopes on the HR2 domain and to the
spacer region between the HR1 and HR2 domains. Using
these MAbs, we could investigate the mechanism of membrane
fusion and virus entry.
In our previous study, the S10 region from residues 1029 to
1192 induced neutralizing antibodies (15). As another S frag-
ment (S9, residues 798 to 1054) containing the residues 1029
to 1054 did not induce neutralizing antibodies, the residues
1055 to 1192 were considered to contain the neutralizing re-
gion. In this study, all the 18 MAbs raised against S10 tar-
geted the sites downstream of residue 1091 but not the region
upstream of residue 1091. These results suggested that anti-
genic sites (I, II, III, and IV) recognized by these MAbs might
be immunodominant in humoral immunity to S10. The neu-
tralizing region has been narrowed down to residues 1091 to
1130 and 1151 to 1192, as the region contained the predomi-
nant antigenic sites.
Our results have shown that MAbs targeting the linear epitopes
on the fusion core of the S2 region of SARS-CoV were able to
neutralize virus infectivity, consistent with results obtained from
the previous work using polyclonal antibodies (15). The neutral-
izing titers of these MAbs against membrane fusion domains were
relatively low compared with the MAbs against the receptor-
binding domain of the SARS S protein (5, 26). However, the
results were consistent with previous findings on murine corona-
virus that the neutralizing titers of MAbs against membrane-
fusion S2 were 3 to 4 orders of magnitude lower than those
against the receptor-binding S1 region (16, 28). In another study,
the binding site of a MAb was mapped to the HR2 domain and
the neutralizing titer was 32 times lower than a MAb against the
receptor-binding site of MHV (40 versus 1,280) (21). The differ-
ent neutralizing titers obtained might be due to the accessibility of
the respective determinants on the S1 and S2 subunits of mature
virions. Nevertheless, anti-S10 polyclonal antibodies against
multiple epitopes do neutralize virus infection more efficiently
than each of these MAbs (targeting a single epitope). It remains
to be investigated if the polyclonal antibodies act cooperatively or
synergistically (40).
Overall, the results of syncytium inhibition by the eight
MAbs were consistent with the results obtained from the virus
neutralization assays. Specific MAbs that could inhibit syncy-
tium formation could also protect cells against in vitro virus
infection. An interesting observation was the less-effective neu-
tralizing property of MAb 1A9 despite its effectiveness at cell-
cell membrane blocking. The reason for this is not clear and
needs further investigation.
The structure of the fusion core of the SARS-CoV S protein
has been determined, demonstrating that residues 1150 to 1184 in
HR2 interacted with residues 902 to 947 of HR1 (27, 35). Bio-
physical and biochemical analysis also revealed that residues 1142
to 1188 of HR2 interacted with residues 896 to 972 of HR1 (12).
Furthermore, another study showed that the interaction domains
Bottom left panel, S was probed with type III MAb 4B12 (solid line) and anti-dengue MAb (dotted line). Bottom right panel, S was probed with
type IV MAb 1G10 (solid line) and anti-dengue MAb (dotted line). (C) Syncytium formation between effector and target cells shown in a bright
field (left panel), a dark field (right panel), and a combination of both (center panel). Top panel, effector cells 293T expressing S and GFP were
mixed with target cells CHO-ACE2 expressing the ACE2 protein. Bottom panel, effector cells 293T expressing N and GFP were mixed with target
cells CHO-ACE2 expressing ACE2 protein. Micrographs were taken at a magnification of 20.
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were mapped to residues 1151 to 1185 of HR2 and residues 916
to 950 of HR1 (30). Evidence shows that HR1 and HR2 form a
six-helix bundle, a structure also observed for other type 1 viral
fusion proteins in their fusion-competent state. The type III and
IV MAbs also bound to these residues in the HR2 domain (res-
idues 1151 to 1170 and 1151 to 1192, respectively) as described
above. Therefore, it is reasonable to assume that the binding of
antibodies to this region upset the interaction of HR1 and
HR2, interfered with the conformational changes, and abol-
ished the fusion activity. A previous study showed that a neu-
FIG. 4. (A) Inhibition of syncytium formation between effector and target cells. Top panel, incubation with rabbit preimmune serum (left) and
rabbit anti-S10 polyclonal antibody (right) at 1:40 dilution. Bottom panel, incubation with mouse anti-dengue ascitic fluid (left) and mouse MAb
1A9 (right) at a 1:40 dilution. Micrographs were taken at a magnification of 10. (B) Dose-dependent inhibition of syncytium formation between
effector cells, 293T-SP, expressing S and target cells, CHO-ACE2, expressing ACE2 in the presence of antibodies at 1:40 (black), 1:80 (white), and
1:160 (gray) dilutions.
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tralizing MAb against the S protein of MHV bound to a linear
epitope (SIAPDLSLDFEKLNV) (Fig. 2) located within the
HR2 domain (21). This MAb also blocked membrane fusion,
indicating that the mechanism involved in neutralization by
these MAbs is the blocking of virus-cell membrane fusion.
Interestingly, type III and IV MAbs also bound to the HR2
domain and display neutralizing and cell-cell fusion inhibition
properties. Our results are consistent with previous studies
showing that the peptides mimicking residues 1161 to 1187
(HR2-18) (36), 1153 to 1189 (CP1) (19), 1126 to 1193 (sHR2-8),
and 1130 to 1189 (sHR2-2) (3) of the HR2 inhibit the propa-
gation of SARS-CoV. These could interact with the HR1 re-
gion, interfere with the formation of the six-helix bundle, and
inhibit membrane fusion.
The type I and II MAbs bound to the sites (residues 1091 to
1130) upstream of residue 1131, which is immediately up-
stream of the HR2 domain beyond the boundaries of the
extended conformation and -helix of the HR2 domain deter-
mined previously (12, 30, 35). The neutralizing mechanism of
type I and II MAbs is unknown. It is likely that the occupancy
of the spacer region between the HR1 and HR2 by a MAb
interferes with the interaction of these two domains by steric
hindrance. If this is the case, our results indicated that the
spacer region, especially the domain immediately upstream of
the HR2 domain, plays an important role in mediating HR1/
HR2 interaction, conformational change, and membrane fu-
sion. The longer spacer region (about 140 to 170 residues)
between the HR1 and HR2 domains is one of the unique char-
acteristics of the S protein of CoV, similar to the paramyxovirus
SV5 F1 protein (250 residues), but different from fusion pro-
teins of other enveloped viruses (5 to 26 residues) (2). It is
believed that the absence of a spacer region or a very short
region between the HR2 and transmembrane domains is com-
pensated for by the presence of a large spacer region between
the HR1 and HR2 domains (12). The spacer region might
provide the flexibility to form a loop so that the trimeric HR1
coiled coil could be packed with the three helices of the HR2
in an anti-parallel manner during the six-helix bundle forma-
tion.
The identification of these novel neutralizing sites could lead
to the development of efficacious vaccines based on peptide
mimics of the linear epitopes. Furthermore, the spacer region
identified in this study might provide a new target for the
development of entry inhibitors. Subunit vaccine candidates
(including HR2 and the spacer region), derived from the neu-
tralizing epitopes identified in this study, could be designed
and tested in animal models for potential usage in the preven-
tion of SARS-CoV infection. Previous work has shown that
a decapeptide homologous to residues 993 to 1002 of the
S protein of murine hepatitis virus strain JHM, located near
the HR1 domain and between the HR1 and HR2 domains,
elicited high levels of neutralizing antibody and protected mice
against lethal virus challenge (29). Recently, a study showed
that a peptide derived from residues 1167 to 1175 within the
HR2 domain of the SARS-CoV S protein could elicit specific
immune responses mediated by cytotoxic T lymphocytes (32).
Thus, molecular dissection of the HR2 domain may finally help
to understand the mechanisms of immune responses and drug
inhibition.
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